News about "Novartis"

Novartis Reports Strong Long-Term Efficacy of Scemblix in Chronic Myeloid Leukemia Trial

Novartis’ Scemblix demonstrated sustained efficacy and a favourable safety profile over nearly three years of follow-up, reinforcing its potential as a frontline treatment option for adults with Philadelphia chromosome-positive chronic myeloid leukemia.

Novartis | 03/06/2026 | By News Bureau

Novartis Expands US Manufacturing and R&D with Seventh Facility

Novartis advances its US expansion plan with a seventh facility, including a new API site in North Carolina to enable end-to-end manufacturing and accelerate delivery of innovative medicines.

Novartis | 04/05/2026 | By News Bureau |  111

Novartis Secures EC Approval for First Oral Targeted CSU Drug Rhapsido

Novartis introduces Rhapsido in Europe, offering a first-of-its-kind oral targeted therapy for patients with chronic spontaneous urticaria.

Novartis | 28/04/2026 | By News Bureau

Novartis Signs Deal with Synnovation Therapeutics to Explore Next-Gen Breast Cancer Treatment

Novartis has signed a deal with Synnovation Therapeutics to advance SNV4818, a next-generation PI3Kα inhibitor in phase-I/II trials, targeting HR+/HER2- breast cancer patients with PIK3CA mutations, addressing a significant unmet need.

Novartis | 20/03/2026 | By News Bureau

US FDA Approves Novartis' Cosentyx for Adolescents with Moderate-to-Severe Hidradenitis Suppurativa

The FDA has approved Novartis’ Cosentyx for patients aged 12 years and above with moderate-to-severe Hidradenitis Suppurativa (HS), marking the therapy’s fourth paediatric indication and expanding treatment options with a differentiated IL-17A mechanism.

Novartis | 16/03/2026 | By News Bureau |  107

Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria

Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.

Novartis | 19/02/2026 | By News Bureau |  242

Novartis Builds Global Biomedical Research Centre in San Diego

Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.

Novartis | 09/02/2026 | By News Bureau |  122

Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026

Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.

Novartis | 05/02/2026 | By Darshana |  758

Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease

The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.

Novartis | 19/01/2026 | By News Bureau |  243

Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies

Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.

Novartis | 13/01/2026 | By Darshana |  358